Serum Hsa_circ_0005962 Is A Prognostic Biomarker of Paclitaxel Resistance in Nonsmall Cell Lung Cancer Treatment

BACKGROUND: Tumor progression and the therapeutic resistance associated with cancer agents are thought to be modulated by circular RNAs (circRNAs); however, its mechanism associated with nonsmall cell lung cancer (NSCLC) is still undetermined. The following investigation aimed to evaluate the involvement of circRNAs with NSCLC. METHODS: The serum specimens of 146 NSCLC individuals who received complete four cycles of PTX chemotherapy were collected. The serum concentration of hsa_circ_0005962 of these individuals was assessed with quantitative real-time polymerase chain reaction (qRT-PCR), followed by the evaluation of demographic and survival consequences for further assessments. RESULTS: It was revealed that hsa_circ_0005962 is substantially increased in NSCLC chemoresistant patients and was positively correlated with the disease stage. Furthermore, the hsa_circ_0005962 value of the area under the curve was moderate, and increased hsa_circ_0005962 expression was linked with shorter overall survival (OS). Hsa_circ_0005962 stimulated paclitaxel resistance (PTX-R) in resistant NSCLC cells by regulating the axis of miR-126-5p/insulin-like growth factor 1 (IGF1). CONCLUSION: The results of this investigation highlight that hsa_circ_0005962 induces chemoresistance in NSCLC patients and, therefore, can act as a physiological target to treat NSCLC.